GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BUE:AZN) » Definitions » Cyclically Adjusted Revenue per Share

AstraZeneca (BUE:AZN) Cyclically Adjusted Revenue per Share : ARS39.33 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is AstraZeneca Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share for the three months ended in Mar. 2024 was ARS6,847.473. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS39.33 for the trailing ten years ended in Mar. 2024.

During the past 12 months, AstraZeneca's average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AstraZeneca was 9.90% per year. The lowest was -0.20% per year. And the median was 4.70% per year.

As of today (2024-05-24), AstraZeneca's current stock price is ARS214.50. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS39.33. AstraZeneca's Cyclically Adjusted PS Ratio of today is 5.45.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.78. The lowest was 2.42. And the median was 3.87.


AstraZeneca Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted Revenue per Share Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.55 43.84 38.93 34.04 38.81

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.66 35.53 36.63 38.81 39.33

Competitive Comparison of AstraZeneca's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.



AstraZeneca Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6847.473/131.6000*131.6000
=6,847.473

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 43.466 99.800 57.316
201409 44.020 100.000 57.930
201412 45.434 99.900 59.851
201503 42.230 99.600 55.798
201506 45.303 100.100 59.559
201509 44.187 100.200 58.034
201512 65.472 100.400 85.818
201603 70.596 100.400 92.534
201606 61.920 101.000 80.680
201609 67.149 101.500 87.062
201612 69.934 102.200 90.052
201703 65.821 102.700 84.343
201706 65.783 103.500 83.643
201709 86.193 104.300 108.754
201712 86.860 105.000 108.865
201803 82.345 105.100 103.108
201806 101.473 105.900 126.099
201809 155.096 106.600 191.469
201812 190.965 107.100 234.650
201903 169.277 107.000 208.195
201906 198.297 107.900 241.853
201909 273.066 108.400 331.508
201912 303.375 108.500 367.965
202003 300.372 108.600 363.987
202006 327.179 108.800 395.742
202009 372.219 109.200 448.572
202012 459.273 109.400 552.471
202103 499.913 109.700 599.713
202106 590.805 111.400 697.935
202109 644.851 112.400 755.003
202112 776.563 114.700 890.982
202203 783.451 116.500 884.997
202206 830.817 120.500 907.349
202209 978.800 122.300 1,053.230
202212 1,204.393 125.300 1,264.949
202303 1,377.658 126.800 1,429.809
202306 1,756.308 129.400 1,786.168
202309 2,577.965 130.100 2,607.688
202312 2,768.281 130.500 2,791.615
202403 6,847.473 131.600 6,847.473

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


AstraZeneca  (BUE:AZN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=214.50/39.33
=5.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.78. The lowest was 2.42. And the median was 3.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AstraZeneca Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (BUE:AZN) Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (BUE:AZN) Headlines

From GuruFocus

AstraZeneca: Growth Is Still a Better Choice

By Nathan Aisenstadt 11-15-2023